Midas Management’s Myriad Genetics MYGN Stock Holding History

Midas Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-6,000	Closed	-$225K	–	167
2016 Q1	$225K	Hold	6,000	–	–	0.12%	148
2015 Q4	$259K	Hold	6,000	–	–	0.15%	123
2015 Q3	$225K	Hold	6,000	–	–	0.15%	108
2015 Q2	$204K	Hold	6,000	–	–	0.11%	116
2015 Q1	$212K	Hold	6,000	–	–	0.11%	122
2014 Q4	$204K	Hold	6,000	–	–	0.11%	124
2014 Q3	$231K	Buy	+6,000	New	+$224K	0.13%	126
2014 Q2	–	Sell	-18,000	Closed	-$615K	–	139
2014 Q1	$615K	Hold	18,000	–	–	0.29%	123
2013 Q4	$378K	Buy	+18,000	New	+$455K	0.18%	136

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Midas Management's MYGN Position: Q2 2016 in Review

Midas Management sold out of Myriad Genetics (MYGN) in Q2 2016, closing a stake of 6,000 shares — an estimated $225K sold.

Midas Management first reported a position in MYGN in Q4 2013 and held it in 9 quarters. The position peaked at $615K in Q1 2014. 252 funds tracked by Wall St. Rank hold MYGN as of Q2 2016.

Midas Management reported no remaining Myriad Genetics position as of Q2 2016 after selling out during the quarter.
Midas Management sold 6,000 Myriad Genetics shares in Q2 2016, an estimated $225K.
Midas Management first reported a position in Myriad Genetics in Q4 2013 and held it in 9 quarters.
Midas Management's Myriad Genetics position peaked at $615K in Q1 2014.
252 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2016.

Based on Midas Management's 13F filing for Q2 2016, filed 28 Jul 2016.